Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

udy, concluding that bavituximab has demonstrated acceptable safety and a predictable PK profile and that a maximum tolerated dose was not reached even at the highest planned dose level. The majority of adverse events reported were mild or moderate in nature.

"The quality of the results generated to date in each of our three ongoing Phase II bavituximab cancer trials is very promising," said Steven W. King, president and CEO of Peregrine. "Our oral presentation today at ASCO exemplifies the heightened interest the bavituximab cancer program is receiving from both clinical researchers and potential partners, and we look forward to reporting on progress and additional results from all three of our Phase II bavituximab studies over the rest of the year."

About Phosphatidylserine (PS)-Targeting Therapies

The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Madison, WI (PRWEB) January 22, 2015 Dr. ... at the 12th annual Scripps Natural Supplements Pre-Conference seminar on ... Supplements Conference is an annual continuing education conference for health ... 15th and included the topic of probiotics in health. Dr. ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... San Antonio (June 30, 2008) Researchers at The University ... Emerging Infectious Diseases and The University of Texas Health Science ... believed to play a role in controlling the early infectious ... bioterrorism agent that is the cause of tularemia. The findings ...
... Fla. -- Researchers have devised an inexpensive way to ... heat energy generated by the sun and other sources. ... Idaho National Laboratory, is the first step toward a ... materials. , While methods to convert the energy into ...
... /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" or ... of British Columbia has issued an interim ... in connection with the previously announced proposed,plan ... the,Company, Calyx Bio-Ventures Inc. ("Calyx"), a wholly-owned ...
Cached Biology Technology:UTSA/UTHSCSA publish results on bio-threat agent 2Flexible nanoantenna arrays capture abundant solar energy 2Flexible nanoantenna arrays capture abundant solar energy 3Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular 2Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular 3
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... February 27, 2012 In a study published in ... the American Academy of Child and Adolescent Psychiatry , ... Children,s Healthcare of Atlanta, and Emory University School of ... cognitive and social disability in children with autism spectrum ...
... to be human in the face of emerging technologies ... hosts Emerge. An unparalleled campus-wide collaboration, Emerge unites ... designers to build, draw, write and rethink the future ... share. Leaders from industry and prominent authors and ...
... that there is a genetic component to intelligence, but a ... genes thought to be linked to intelligence are probably not ... roots may still be a long way off. ... Professor of Economics, and Christopher F. Chabris ,88, PhD ,99, ...
Cached Biology News:Eye-tracking reveals variability in successful social strategies for children with autism 2Emerge attracts futurists to collaborate with scientists, designers artists is redesign of future 2Emerge attracts futurists to collaborate with scientists, designers artists is redesign of future 3In the genes, but which ones? 2In the genes, but which ones? 3